Drug Trial Radar · NCT03564340
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
890
Planned (sponsor's estimate)
Start
May 21, 2018
Primary completion
May 10, 2027
Study completion May 10, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jun 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)
Conditions
- Recurrent Ovarian Cancer
- Recurrent Fallopian Tube Cancer
- Recurrent Primary Peritoneal Cancer
- Recurrent Endometrial Cancer
- Endometrial Cancer
- Low-grade Serous Ovarian Cancer
Interventions
UbamatamabDrug
Administered per the protocol
CemiplimabDrug
Administered per the protocol
SarilumabDrug
Administered per the protocol
TocilizumabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapyTime frame: From Cycle 1, Day 1 up to 35 days
- Number of participants with DLTs for ubamatamab with cemiplimabTime frame: From Cycle 2, Day 1 up to 21 days
- Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for ubamatamab monotherapyTime frame: Up to 2 years
- Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimabTime frame: Up to 2 years
- Number of participants with serious adverse events (SAEs) for ubamatamab monotherapyTime frame: Up to 2 years
- Number of participants with SAEs for ubamatamab with cemiplimabTime frame: Up to 2 years
- Number of deaths for ubamatamab monotherapyTime frame: Up to 2 years
- Number of deaths for ubamatamab with cemiplimabTime frame: Up to 2 years
- Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for ubamatamab monotherapyTime frame: Up to 2 years
- Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab with cemiplimabTime frame: Up to 2 years
- Concentration of ubamatamab in serum over time for ubamatamab monotherapyTime frame: Up to 2 years
- Concentration of ubamatamab in serum over time for ubamatamab with cemiplimabTime frame: Up to 2 years
- Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for ubamatamab monotherapyTime frame: Up to 2 years
- ORR defined by RECIST 1.1 for ubamatamab with cemiplimabTime frame: Up to 2 years
Locations
54 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama_6th Ave
Birmingham, Alabama · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber / Harvard Cancer Center
Boston, Massachusetts · Recruiting
Mayo Clinic - Rochester
Rochester, Minnesota · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Withdrawn
Columbia University Medical Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Completed
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Peter MacCallum Cancer Center
Melbourne, Australia · Completed
Prince of Wales Hospital
Randwick, New South Wales, Australia · Completed
Universitair Ziekenhuis Antwerpen
Edegem, Antwerp, Belgium · Recruiting
Grand Hopital de Charleroi
Charleroi, Hainaut, Belgium · Recruiting
UZLeuven
Leuven, Vlaams-Brabant, Belgium · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
Hopital Lyon Sud
Pierre-Bénite, Auvergne-Rhône, France · Recruiting
Centre Georges Francois Leclerc
Dijon, Bourgogne-Franche-Comté, France · Recruiting
Institut Gustave Roussy
Villejuif, Île-de-France Region, France · Recruiting
Institut Bergonie
Bordeaux, New Aquitaine, France · Recruiting
Centre Francois Baclesse (CFB)
Caen, Normandy, France · Recruiting
Centre Antoine Lacassagne
Nice, Provence Alpes Cote dAzur, France · Recruiting
Rambam Health Care Campus
Haifa, Israel · Recruiting
Sharet Institute of Oncology
Jerusalem, Israel · Recruiting
Sheba Medical Center
Tel HaShomer, Israel · Recruiting
Humanitas S. Pio X
Milan, Italy · Recruiting
Istituto Europeo di Oncologia
Milan, Italy · Recruiting
Instituto Nazionale Tumori- Fondazione Pascale
Naples, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Lazio, Italy · Recruiting
University Medical Center Groningen
Groningen, Netherlands · Recruiting
Radboudumc
Nijmegen, Gelderland, Netherlands · Recruiting
Erasmus MC
Rotterdam, South Holland, Netherlands · Recruiting
Yonsei University Health System
Seoul, South Korea · Recruiting
Asan Medical Center, Univ. of Ulsan
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Korea University Guro Hospital
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Institut Catala dOncologia Badalona
Badalona, Spain · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.